News

Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD

Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels   Clinically relevant secondary endpoints were also met, including statistically significant, progressive improvements in COPD symptoms RPL554 was well tolerated at all dose levels in this four week 400 patient study Management to hold conference call and webcast today [...]

2018-03-27T10:04:15+00:00 March 26th, 2018|News|

MedaPhor Group plc – Opening of Hong Kong office

MedaPhor Group plc (“MedaPhor” or the “Group” or the “Company”) Opening of Hong Kong office MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that it has opened an office in Hong Kong to facilitate the Group’s established reseller network and growing customer base in the Asia-Pacific (APAC) region. The Group [...]

2018-02-25T15:38:22+00:00 February 21st, 2018|News|

MedaPhor Group plc – Launch of new Point-of-Care Ultrasound simulator

MedaPhor Group plc (“MedaPhor” or the “Group” or the “Company”) Launch of new Point-of-Care Ultrasound simulator MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces the launch of its new BodyWorks Eve simulator platform, an ultra-realistic manikin-based simulator to train medical professionals practising Point-of-Care Ultrasound (PoCUS) across emergency medicine and critical [...]

2018-02-25T15:47:57+00:00 February 19th, 2018|News|

Cancer Care In North East Takes Step Forward With Arrival Of First Proton Beam Therapy System

6th February 2018: The first proton beam therapy system to be installed in the North-East of England was delivered today by Proton Partners International Ltd. The arrival of the machine at The Rutherford Cancer Centre, North East, at Bedlington, Northumberland, is another milestone in the provision of innovative cancer care in the UK. Proton Partners International has already [...]

2018-02-25T15:44:38+00:00 February 6th, 2018|News|

MedaPhor Group plc – Acquisition & Placing to raise £5.5m

This announcement contains inside information which, prior to its disclosure, was inside information for the purposes of the Market Abuse Regulation (Article 7 of Regulation (EU) No 596/2014. MedaPhor Group plc (“MedaPhor” or the “Group” or the “Company”) Acquisition and Placing Acquisition of deep-learning image analysis company, Intelligent Ultrasound, for up to £3.6m & Placing to raise £5.5m MedaPhor [...]

2017-09-20T10:33:33+00:00 September 20th, 2017|News|

Dosing of First Patient with investigational agent OMO-1

OCTIMET Oncology NV, the Belgian life science company with a focus on the development of MET kinase inhibitory drug candidates having additional differentiating properties, is pleased to announce the dosing of OMO-1 to the first patient. The multicenter, Phase I/II clinical trial (NCT03138083) is primarily evaluating the safety, pharmacokinetics and tolerability, alone and in combination [...]

2017-08-30T15:51:33+00:00 August 29th, 2017|News|

MedaPhor: Installation of 500th simulation system

MedaPhor Group plc (AIM: MED), the global provider of advanced ultrasound training simulators for medical professionals, announces it has sold its 500th simulation system, with the installation of a HeartWorks TTE Mobile echocardiography skills simulator at Penn State Health Milton S. Hershey Medical Center’s Clinical Simulation Center. MedaPhor’s ScanTrainer and HeartWorks product ranges offer clinicians [...]

2017-08-17T11:11:56+00:00 August 17th, 2017|News|